Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company focused on gene-editing therapies, held its shareholders general meeting on June 26, 2025. With approximately 57% of voting rights exercised, shareholders approved 25 out of 26 resolutions.
The meeting resulted in significant board changes: Mr. André Muller, current CEO of Idorsia Pharmaceuticals, was appointed as a new board member, while Mr. Pierre Bastid resigned and Mr. Axel-Sven Malkomes' term expired. Muller brings extensive experience from his roles at Idorsia, Actelion Pharmaceuticals, and Pierre Fabre SA.
Cellectis (NASDAQ:CLLS), una società biotecnologica in fase clinica specializzata in terapie di editing genico, ha tenuto l'assemblea generale degli azionisti il 26 giugno 2025. Con circa il 57% dei diritti di voto esercitati, gli azionisti hanno approvato 25 delle 26 delibere.
L'assemblea ha portato a importanti cambiamenti nel consiglio di amministrazione: il Sig. André Muller, attuale CEO di Idorsia Pharmaceuticals, è stato nominato nuovo membro del consiglio, mentre il Sig. Pierre Bastid si è dimesso e il mandato del Sig. Axel-Sven Malkomes è scaduto. Muller apporta una vasta esperienza derivante dai suoi ruoli in Idorsia, Actelion Pharmaceuticals e Pierre Fabre SA.
Cellectis (NASDAQ:CLLS), una empresa biotecnológica en etapa clínica centrada en terapias de edición genética, celebró su junta general de accionistas el 26 de junio de 2025. Con aproximadamente el 57% de los derechos de voto ejercidos, los accionistas aprobaron 25 de las 26 resoluciones.
La reunión resultó en cambios significativos en la junta directiva: el Sr. André Muller, actual CEO de Idorsia Pharmaceuticals, fue nombrado nuevo miembro de la junta, mientras que el Sr. Pierre Bastid renunció y el mandato del Sr. Axel-Sven Malkomes expiró. Muller aporta una amplia experiencia de sus roles en Idorsia, Actelion Pharmaceuticals y Pierre Fabre SA.
Cellectis (NASDAQ:CLLS)는 유전자 편집 치료제에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 6월 26일 주주 총회를 개최했습니다. 약 57%의 의결권이 행사된 가운데, 주주들은 26개 안건 중 25개를 승인했습니다.
회의 결과 이사회에 중요한 변화가 있었습니다: 현재 Idorsia Pharmaceuticals의 CEO인 안드레 뮐러 씨가 신규 이사로 임명되었으며, 피에르 바스티드 씨는 사임했고 악셀-스벤 말코메스 씨의 임기는 만료되었습니다. 뮐러 씨는 Idorsia, Actelion Pharmaceuticals, Pierre Fabre SA에서의 경력을 통해 풍부한 경험을 보유하고 있습니다.
Cellectis (NASDAQ:CLLS), une société biotechnologique en phase clinique spécialisée dans les thérapies d'édition génétique, a tenu son assemblée générale des actionnaires le 26 juin 2025. Avec environ 57% des droits de vote exercés, les actionnaires ont approuvé 25 des 26 résolutions.
La réunion a entraîné des changements importants au sein du conseil d'administration : M. André Muller, actuel PDG d'Idorsia Pharmaceuticals, a été nommé nouveau membre du conseil, tandis que M. Pierre Bastid a démissionné et que le mandat de M. Axel-Sven Malkomes a pris fin. Muller apporte une vaste expérience acquise lors de ses fonctions chez Idorsia, Actelion Pharmaceuticals et Pierre Fabre SA.
Cellectis (NASDAQ:CLLS), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf Gen-Editing-Therapien, hielt am 26. Juni 2025 seine Hauptversammlung ab. Mit etwa 57% der ausgeübten Stimmrechte genehmigten die Aktionäre 25 von 26 Beschlüssen.
Die Versammlung führte zu bedeutenden Veränderungen im Vorstand: Herr André Muller, derzeitiger CEO von Idorsia Pharmaceuticals, wurde als neues Vorstandsmitglied ernannt, während Herr Pierre Bastid zurücktrat und die Amtszeit von Herrn Axel-Sven Malkomes ablief. Muller bringt umfassende Erfahrung aus seinen Tätigkeiten bei Idorsia, Actelion Pharmaceuticals und Pierre Fabre SA mit.
- None.
- None.
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
At the meeting, during which approximately
The Cellectis shareholders' meeting appointed Mr. André Muller as a member of the Company's Board of Directors, with immediate effect. In addition, at the close of the AGM, the term of Mr Axel-Sven Malkomes expired, and the previously announced resignation of Mr. Pierre Bastid became effective.
Mr. Muller serves currently (and this until July 1st, 2025) as Chief Executive Officer of Idorsia Pharmaceuticals, Ltd. a listed Swiss biotech company. Previously, Mr. Muller served as Chief Financial Officer of Idorsia Pharmaceuticals, Ltd. and Actelion Pharmaceuticals, Ltd. He held various financial positions at Pierre Fabre SA, an international pharmaceutical and dermo-cosmetics company. Mr. Muller holds a Master's degree in Business Administration from the EMLYON Business School in Lyon.
"We are honored to welcome Mr. André Muller to the Cellectis’ Board of Directors as a director. His extensive experience will be an invaluable asset to the Company. We would also like to express our gratitude to Mr. Pierre Bastid and Mr. Axel Sven-Malkomes, whose directorships terminated at the end of this meeting. Their contribution over the last few years has been exceptional, and their precious support has greatly contributed to the advancement of the Company's strategy," said Jean-Pierre Garnier, Chairman of the Board of Directors of Cellectis.
The detailed results of the vote and the resolutions are available on Cellectis’ website:
https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
Who was appointed to Cellectis (CLLS) Board of Directors in June 2025?
What was the voting outcome at Cellectis' June 2025 shareholders meeting?
Which board members left Cellectis (CLLS) after the June 2025 meeting?
What is André Muller's background before joining Cellectis' board?
